Brief: Cabaletta Bio Inc Reports New Data From RESET-PV Trial
09/10/2025 17:23
Oct 9 (Reuters) - Cabaletta Bio Inc CABA.O: CABALETTA BIO INC - REPORTS NEW DATA FROM RESET-PV TRIAL - SEC FILING CABALETTA BIO INC - RESE-CEL WELL TOLERATED WITH NO ICANS REPORTED - SEC FILING CABALETTA BIO INC - ALL THREE PATIENTS EXPERIENCED SUBSTANTIAL DEPLETION OF B CELLS WITHIN THE FIRST MONTH POST-INFUSION CABALETTA BIO INC - PATIENTS 2 AND 3 ACHIEVED COMPLETE PERIPHERAL B CELL DEPLETION Source text: [ID:n0001193125-25-235533] Further company coverage: CABA.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity